Back
Compare AU
Compare CETF vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the VanEck FTSE China A50 ETF (CETF) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CETF | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 40 | 78 |
Median incremental investment | $1,000.00 | $678.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,050.88 | $2,353.08 |
Average age group | > 35 | > 35 |
Key Summary
CETF | CURE | |
|---|---|---|
Strategy | CETF.AX was created on 2015-06-26 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 34.35m in AUM and 51 holdings. The Fund seeks to provide investors with access to a portfolio of the 50 largest companies in the mainland Chinese market. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 51.24m in AUM and 148 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Kweichow Moutai Co Ltd Class A (8.00 %) Contemporary Amperex Technology Co Ltd Class A (7.55 %) Zhongji Innolight Co Ltd Class A (4.43 %) | Moderna Inc (3.01 %) Twist Bioscience Corp (1.78 %) Halozyme Therapeutics Inc (1.43 %) |
Top 3 industries | Financials (34.11 %) Consumer Staples (28.51 %) Other (22.20 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | China (98.90 %) Hong Kong (0.94 %) United States (0.16 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.6 % | 0.45 % |
Key Summary
CETF | CURE | |
|---|---|---|
Issuer | VanEck | Global X |
Tracking index | FTSE China A50 Index - CNY | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.6 % | 0.45 % |
Price | $60.07 | $77.25 |
Size | $33.995 million | $50.449 million |
10Y return | 14.75 % | N/A |
Annual distribution yield (5Y) | 2.03 % | 0.03 % |
Market | ASX | ASX |
First listed date | 26/06/2015 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CETF | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 40 | 78 |
Median incremental investment | $1,000.00 | $678.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,050.88 | $2,353.08 |
Average age group | > 35 | > 35 |
Pros and Cons
CETF | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CETF | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |